Treatment outcomes and prognostic factors of patients with lymphoblastic lymphoma in East Asia.
Medicine (Baltimore)
; 103(7): e37100, 2024 Feb 16.
Article
en En
| MEDLINE
| ID: mdl-38363899
ABSTRACT
Lymphoblastic lymphoma (LBL) is a rare, aggressive non-Hodgkin lymphoma (NHL) that has no established therapeutic approaches. The aim of this study was to investigate optimal treatments and prognostic risk models for patients with LBL in East Asia. We retrospectively examined the clinical data and treatment courses of adult patients diagnosed as LBL by WHO 2017 classification system. Median overall survival (OS) of the 78 patients with LBL was 38.3 months. There was no significant difference in OS between the patients who were treated with acute lymphoblastic leukemia (ALL)-like protocols and with NHL-like protocols (72.4 months vs 37.5 months, respectively, Pâ
=â
.546). The patients treated with ALL-like protocols had significantly shorter progression-free survival (PFS) (median 11.7 months for ALL-like protocols vs 27.0 months for NHL-like protocols, Pâ
=â
.030). A multivariable analysis found that central nervous system (CNS) prophylaxis, relapse of CNS lesions, leukemic transformation, and response to initial treatment were risk factors for OS of patients with LBL. Hematopoietic stem cell transplantation had no survival benefit, compared with chemotherapy-only treatment. Less intensive chemotherapy may be more optimal for patients in East Asia. Prophylaxis and management of CNS lesions should be emphasized throughout the treatment of LBL.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Linfoma no Hodgkin
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
País/Región como asunto:
Asia
Idioma:
En
Revista:
Medicine (Baltimore)
Año:
2024
Tipo del documento:
Article